Significant Ownership of ARCH Venture Fund IX, L.P.

Signature - Title
ARCH Venture Partners IX, L.P. - its General Partner
Location
Chicago, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by ARCH Venture Fund IX, L.P..

Follow Filing Activity

Follow ARCH Venture Fund IX, L.P. and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sponsored

Significant Ownership of ARCH Venture Fund IX, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SANA Sana Biotechnology, Inc. Common Stock, par value $0.0001 per share 17% $163,630,594 46,093,125 Robert Nelsen 30 Sep 2025
LYEL Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share 13% $17,200,927 36,597,716 Robert Nelsen 31 Dec 2024
LYEL Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share 13% $44,807,053 2,759,072 ARCH Venture Fund IX, L.P. 30 Sep 2025
VIR Vir Biotechnology, Inc. Common Stock, $0.0001 par value 8.5% $101,645,627 13,534,704 Robert Nelsen 27 Feb 2026
BEAM Beam Therapeutics Inc. Common Stock par value $0.01 per share 4.6% $90,680,723 4,600,747 0% Robert Nelsen 31 Mar 2025
OMIC Singular Genomics Systems, Inc. Common Stock par value $0.0001 per share 0% $0 0 ARCH Venture Fund IX, L.P. 21 Feb 2025

Schedules 13D/G Reported by ARCH Venture Fund IX, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.